{"id":296219,"date":"2026-05-29T00:00:00","date_gmt":"2026-05-29T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0008-2024-biopharma-systemic-lupus-erythematosus-unmet-need-unmet-need-moderate-to-severe\/"},"modified":"2026-06-19T11:09:13","modified_gmt":"2026-06-19T11:09:13","slug":"unneim0008-2026-biopharma-systemic-lupus-erythematosus-unmet-need-unmet-need-moderate-to-severe-systemic-lupus","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0008-2026-biopharma-systemic-lupus-erythematosus-unmet-need-unmet-need-moderate-to-severe-systemic-lupus\/","title":{"rendered":"Systemic Lupus Erythematosus &#8211; Unmet Need &#8211; Unmet Need &#8211; Moderate to Severe Systemic Lupus Erythematosus (US\/EU)"},"content":{"rendered":"<p>Systemic lupus erythematosus (<abbr data-abbreviation-entity=\"5137\" title=\"systemic lupus erythematosus\">SLE<\/abbr>) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious renal and <abbr data-abbreviation-entity=\"4768\" title=\"central nervous system\">CNS<\/abbr> manifestations. Most drugs used to treat <abbr data-abbreviation-entity=\"5137\" title=\"systemic lupus erythematosus\">SLE<\/abbr> are older, generically available, and off-label. To date, GlaxoSmithKline\u2019s Benlysta and AstraZeneca\u2019s Saphnelo\u2014both viewed by many physicians as only modestly effective\u2014are the only drugs approved for moderate to severe <abbr data-abbreviation-entity=\"5137\" title=\"systemic lupus erythematosus\">SLE<\/abbr> (excluding severe active renal and severe active <abbr data-abbreviation-entity=\"4768\" title=\"central nervous system\">CNS<\/abbr> manifestations). Thus, unmet need remains high in the moderate to severe subpopulation, leaving significant commercial opportunity for novel <abbr data-abbreviation-entity=\"5137\" title=\"systemic lupus erythematosus\">SLE<\/abbr> therapies that are more efficacious than Benlysta and Saphnelo.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the treatment drivers and goals in moderate to severe <abbr data-abbreviation-entity=\"5137\" title=\"systemic lupus erythematosus\">SLE<\/abbr> (excluding severe active renal and severe active <abbr data-abbreviation-entity=\"4768\" title=\"central nervous system\">CNS<\/abbr> manifestations)? How do current therapies perform on key treatment drivers and goals for moderate to severe <abbr data-abbreviation-entity=\"5137\" title=\"systemic lupus erythematosus\">SLE<\/abbr>?<\/li>\n<li>Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in the treatment of moderate to severe <abbr data-abbreviation-entity=\"5137\" title=\"systemic lupus erythematosus\">SLE<\/abbr>?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to rheumatologists for a hypothetical new drug for moderate to severe <abbr data-abbreviation-entity=\"5137\" title=\"systemic lupus erythematosus\">SLE<\/abbr>?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p><a>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/a><\/p>\n<ul class=\"round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<li>Analyze market scenarios for different target product profiles using the <abbr data-abbreviation-entity=\"6194\" title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/li>\n<\/ul>\n<p><strong>Key feature:<\/strong><\/p>\n<p>Target Product Profile (<abbr data-abbreviation-entity=\"6194\" title=\"Target Product Profile\">TPP<\/abbr>) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven <abbr data-abbreviation-entity=\"6194\" title=\"Target Product Profile\">TPP<\/abbr>s across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n<p><strong>Markets covered: <\/strong>United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 33 European rheumatologists fielded in January 2026<\/p>\n<p><strong>Key companies: <\/strong>GlaxoSmithKline, AstraZeneca, Genentech, Sandoz, Sanofi<\/p>\n<p><strong>Key drugs: <\/strong>Benlysta (<abbr data-abbreviation-entity=\"4871\" title=\"intravenous\">IV<\/abbr> and <abbr data-abbreviation-entity=\"4958\" title=\"subcutaneous\">SC<\/abbr>), Saphnelo, Rituxan \/ MabThera, CellCept, azathioprine, hydroxychloroquine<\/p>\n","protected":false},"template":"","class_list":["post-296219","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatology","biopharma-therapy-areas-systemic-lupus-erythematosus","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296219","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296219"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}